Biomarkers of Cholestasis and Liver Injury in the Early Phase of Acute Respiratory Distress Syndrome and Their Pathophysiological Value.
ARDS
GGT
bile acids
cholestasis
liver injury
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
14 Dec 2021
14 Dec 2021
Historique:
received:
30
09
2021
revised:
17
11
2021
accepted:
13
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
Impaired liver function and cholestasis are frequent findings in critically ill patients and are associated with poor outcomes. We tested the hypothesis that hypoxic liver injury and hypoxic cholangiocyte injury are detectable very early in patients with ARDS, may depend on the severity of hypoxemia, and may be aggravated by the use of rescue therapies (high PEEP level and prone positioning) but could be attenuated by extracorporeal membrane oxygenation (ECMO). In 70 patients with ARDS, aspartate-aminotransferase (AST), alanin-aminotransferase (ALT) and gamma glutamyltransferase (GGT) were measured on the day of the diagnosis of ARDS and three more consecutive days (day 3, day 5, day 10), total bile acids were measured on day 0, 3, and 5. AST levels increased on day 0 and remained constant until day 5, then dropped to normal on day 10 (day 0: 66.5 U/l; day 3: 60.5 U/l; day 5: 63.5 U/l, day 10: 32.1 U/l), ALT levels showed the exact opposite kinetic. GGT was already elevated on day 0 (91.5 U/l) and increased further throughout (day 3: 163.5 U/l, day 5: 213 U/l, day 10: 307 U/l), total bile acids levels increased significantly from day 0 to day 3 ( We found no evidence of hypoxic liver injury or hypoxic damage to cholangiocytes being caused by the severity of hypoxemia in ARDS patients during the very early phase of the disease. Additionally, mean PEEP level, prone positioning, and ECMO treatment did not have an impact in this regard. Nevertheless, GGT levels were elevated from day zero and rising, this increase was not related to paO
Sections du résumé
BACKGROUND
BACKGROUND
Impaired liver function and cholestasis are frequent findings in critically ill patients and are associated with poor outcomes. We tested the hypothesis that hypoxic liver injury and hypoxic cholangiocyte injury are detectable very early in patients with ARDS, may depend on the severity of hypoxemia, and may be aggravated by the use of rescue therapies (high PEEP level and prone positioning) but could be attenuated by extracorporeal membrane oxygenation (ECMO).
METHODS
METHODS
In 70 patients with ARDS, aspartate-aminotransferase (AST), alanin-aminotransferase (ALT) and gamma glutamyltransferase (GGT) were measured on the day of the diagnosis of ARDS and three more consecutive days (day 3, day 5, day 10), total bile acids were measured on day 0, 3, and 5.
RESULTS
RESULTS
AST levels increased on day 0 and remained constant until day 5, then dropped to normal on day 10 (day 0: 66.5 U/l; day 3: 60.5 U/l; day 5: 63.5 U/l, day 10: 32.1 U/l), ALT levels showed the exact opposite kinetic. GGT was already elevated on day 0 (91.5 U/l) and increased further throughout (day 3: 163.5 U/l, day 5: 213 U/l, day 10: 307 U/l), total bile acids levels increased significantly from day 0 to day 3 (
CONCLUSIONS
CONCLUSIONS
We found no evidence of hypoxic liver injury or hypoxic damage to cholangiocytes being caused by the severity of hypoxemia in ARDS patients during the very early phase of the disease. Additionally, mean PEEP level, prone positioning, and ECMO treatment did not have an impact in this regard. Nevertheless, GGT levels were elevated from day zero and rising, this increase was not related to paO
Identifiants
pubmed: 34943592
pii: diagnostics11122356
doi: 10.3390/diagnostics11122356
pmc: PMC8699895
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Biochem. 1984 Aug;96(2):289-97
pubmed: 6150032
Intern Med. 2007;46(14):1063-70
pubmed: 17634701
BMC Health Serv Res. 2015 Dec 17;15:563
pubmed: 26677970
J Clin Anesth. 2010 Mar;22(2):104-9
pubmed: 20304351
J Clin Med. 2020 Nov 26;9(12):
pubmed: 33256244
Crit Care. 2015 Mar 31;19:131
pubmed: 25886728
Am J Respir Crit Care Med. 1995 Aug;152(2):504-10
pubmed: 7633699
Crit Care. 2007;11(6):175
pubmed: 18001503
Front Med. 2014 Mar;8(1):118-26
pubmed: 24415157
Am J Med. 2000 Aug 1;109(2):109-13
pubmed: 10967151
Am J Gastroenterol. 2007 Jun;102(6):1221-9
pubmed: 17531010
Crit Care. 2005 Jun;9(3):R251-7
pubmed: 15987398
Int J Biol Sci. 2012;8(9):1237-47
pubmed: 23136552
Am J Respir Crit Care Med. 2012 Oct 1;186(7):640-7
pubmed: 22837381
Hum Pathol. 1994 Sep;25(9):940-6
pubmed: 8088771
Scand J Gastroenterol. 2011 Apr;46(4):471-8
pubmed: 21114429
Am J Gastroenterol. 1995 Aug;90(8):1244-5
pubmed: 7639223
Intensive Care Med. 2016 May;42(5):699-711
pubmed: 27040102
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1498-1506
pubmed: 28882625
Cell Mol Gastroenterol Hepatol. 2021;12(1):25-40
pubmed: 33545429
Med Clin North Am. 2014 Jan;98(1):1-16
pubmed: 24266911
Intensive Care Med. 2006 Oct;32(10):1584-90
pubmed: 16941166
Shock. 2009 Oct;32(4):358-65
pubmed: 19197231
Microorganisms. 2020 Dec 16;8(12):
pubmed: 33339330
J Hepatol. 1995 Jun;22(6):658-70
pubmed: 7560859
Enzyme. 1982;28(1):3-13
pubmed: 6126356
Int J Clin Monit Comput. 1986;3(2):103-6
pubmed: 3537175
Curr Opin Crit Care. 2006 Apr;12(2):160-5
pubmed: 16543794
Neurotherapeutics. 2012 Jan;9(1):17-23
pubmed: 22105793
Endoscopy. 2008 Mar;40(3):214-8
pubmed: 18264887
Hepatology. 1999 Feb;29(2):427-33
pubmed: 9918919
Intensive Care Med. 2011 Aug;37(8):1302-10
pubmed: 21647720
Crit Care Med. 2007 Apr;35(4):1099-104
pubmed: 17334250
Intensive Care Med. 2009 Aug;35(8):1397-405
pubmed: 19506833
Circulation. 1960 May;21:646-60
pubmed: 14409072
J Clin Gastroenterol. 1997 Jun;24(4):245-9
pubmed: 9252850
Semin Liver Dis. 2004 Feb;24(1):21-42
pubmed: 15085484
Gut. 1999 Jul;45(1):129-33
pubmed: 10369716
Crit Care Med. 1982 Nov;10(11):703-5
pubmed: 6754257
Medicine (Baltimore). 2003 Nov;82(6):392-406
pubmed: 14663289
Anaesthesia. 2016 May;71(5):550-5
pubmed: 26948476
CMAJ. 2021 Mar 1;193(9):E310
pubmed: 33649170
N Engl J Med. 2019 Jul 18;381(3):264-273
pubmed: 31314970
J Antimicrob Chemother. 2011 Apr;66 Suppl 2:ii33-40
pubmed: 21398306
Mayo Clin Proc. 2006 Sep;81(9):1232-6
pubmed: 16970220
Biochem Pharmacol. 1995 Oct 12;50(8):1223-32
pubmed: 7488238
Wien Klin Wochenschr. 2010 Mar;122(5-6):129-39
pubmed: 20361374
Crit Care. 2016 Apr 06;20:86
pubmed: 27048605